Chronic myeloid leukemia (CML) is a hematopoietic disorder caused by a translocation occurring between chromosome 22 and chromosome 9, leading to the formation of the Philadelphia chromosome (Ph) and the BCR-ABL fusion gene. The oncogenic protein tyrosine kinase expressed by this gene fusion, Bcr-Abl, is the underlying cause of CML.
The Abl kinase inhibitor imatinib was registered for clinical use in 2001 and is now the current first-line treatment for CML. Beside the activity against Abl, imatinib can also inhibit plateletderived growth factor receptor-b and c-Kit, which is believed to contribute to a number of side effects such as edema, muscle cramps, skin rash, pigmentation and low-grade inhibition of normal hemopoiesis. In addition, imatinib is unable to eradicate the leukemic cells and resistance to it can develop, especially in advanced patients, thus leading to short-term remissions. 1 Resistant clones carrying point mutations on Bcr-Abl protein sequence can be found in approximately 50% of patients with advanced disease.
Recently, several new inhibitors have been developed with the aim of increasing both potency and selectivity against Abl. Among them, bosutinib (SKI-606; Wyeth, Pearl River, NY, USA) is a dual Src/Abl inhibitor that possesses an in vitro activity in the low nanomolar range on several Bcr-Abl-positive cell lines and it is presently in phase III clinical trials. 2 Bosutinib is devoid of activity against platelet-derived growth factor receptor and c-Kit. In addition, structural and modeling data suggest that bosutinib binds an intermediate/active conformation of Bcr-Abl, whereas imatinib binds only the inactive conformation of Bcr-Abl. 2 Moreover, in a recently published in vitro screening study, bosutinib was tested against a panel of the most frequent imatinibresistant Bcr-Abl mutants and was found to have activity against the large majority of them. 3 Bosutinib also possesses additional inhibitory activities absent in the imatinib inhibition profile. 4 Considering the differences in the binding features and in the selectivity profiles between bosutinib and imatinib, a combination of these two drugs might be more effective than single agent treatment in reducing the risk of selecting resistant clones.
In this paper, we report the synergistic cooperation between bosutinib and imatinib in several Bcr-Abl-positive cell lines as well as in samples derived from patients with CML.
Bosutinib was provided by Wyeth, whereas imatinib was synthesized by Dr Enrico Rosso (University of Venice, Italy). The antiproliferative activity for the single agents as well as for the combined treatment was assessed by thymidine incorporation assay.
Bosutinib was tested in combination with imatinib on a panel of Bcr-Abl-positive cell lines across a wide range of concentrations and at different bosutinib/imatinib ratios (1:3, 1:10 and 1:33). The concentrations tested were equally distributed around the IC 50 values as suggested by Chou and co-workers. 5 The combination indices (CI) calculated are reported in Table 1 and proliferation studies are presented in Figure 1a . For all the cell lines tested, the CI indicates an extremely positive cooperation for imatinib and bosutinib that range from strong synergism for KCl22 and Lama84 to very strong synergism in the case of K562 and KU812. When tested against the Bcr-Ablnegative U937 cell line, no effects on proliferation were observed (data not shown). The effect of the combined treatment against murine pro-B Ba/F3 cells expressing p210Bcr-Abl wild type was also evaluated, and showed a synergistic effect (Table 1) , whereas no increase in the toxicity was observed on Ba/F3 parental cells (data not shown).
To investigate whether the use of imatinib in combination with bosutinib can overcome resistance to imatinib treatment, we tested the two drugs in combination on several Bcr-Abl-positive cell lines resistant to imatinib. The results of the proliferation experiments performed using different ratios are presented in Table 1 and Figure 1b . In this setting, the data indicate that the combination of imatinib with bosutinib produced a synergistic inhibitory effect on proliferation, although to a lesser degree than observed in imatinib-sensitive lines. The different behavior of cell lines resistant to imatinib could be due to the differences in the resistance mechanisms: Lama84R presents an increased BcrAbl expression level due to BCR-ABL gene amplification, 6 a mechanism of resistance alternative to Bcr-Abl mutation. The resistance mechanism in KCl22R and K562R has not been clarified yet, but amplification of BCR-ABL and mutations have been excluded. Despite the differences in resistance mechanisms, the synergy levels achievable by the combination in these cell lines are comparable. The highly statistically significant difference between cells sensitive and resistant to imatinib obtained by t-test analysis on CI average values reported in Table 1 (Po0.001) confirm that the combination represents a relevant improvement when no or only limited level of resistance are present. To investigate the effect of the combination against resistant cells carrying point mutations in Bcr-Abl sequence, the Ba/F3 murine cell line was stably transfected with pcDNA3 vector containing either the wild-type or the selected mutated forms of BCR-ABL. Imatinib and bosutinib were combined in proliferation assay against Ba/F3 cells expressing Bcr-Abl Y253F, Bcr-Abl F317L, Bcr-Abl F359V and Bcr-Abl L384M. These mutants are known to be associated with high-level resistance to imatinib treatment in patients with CML. 7 CI calculated show that varying degrees of synergism are present, ranging from slight synergism for Y253F and F317L to synergism for F359V. Treatment of the highly resistant E255K and T315I mutants with the combination resulted in no synergistic effect (data not shown). We observed different levels of synergism that generally correlate with the resistance level observed for single drugs. 3 In fact, no positive cooperation is present against the T315I that is defined as highly resistant to both tyrosine kinase inhibitors, whereas synergistic activity is more evident in those mutants that are sensitive or slightly resistant to one of the two drugs. We next investigated whether the coadministration of imatinib and bosutinib could affect the induction of cell death in Bcr-Ablpositive cell lines. KU812 and K562 imatinib-sensitive cells were treated with selected concentrations of both inhibitors for 48 h and cell-cycle distribution was determined by flow cytometric analysis ( Figure 2 ). The combined treatment resulted in higher percentages of dead cells in both cell lines tested, compared to each inhibitor used as single agent, but the difference did not achieve statistical significance.
Because CrkL is a target of Bcr-Abl commonly used to evaluate the oncoprotein kinase activity, we investigated whether the combined treatment could affect its phosphorylation level in K562 and KU812. Following 2h exposure to the drugs as single agents or in combination, the effect of the drug treatment in the reduction of CrkL cellular phosphorylation was evaluated by western blot analysis on total cell lysates. The densitometry analysis of the anti-phospho CrkL signal normalized over anti-actin revealed a more pronounced reduction in cellular CrkL phosphorylation for the combination in comparison with single treatments (data not shown).
The analysis performed on fresh leukemic cells derived from Ph þ patients with different disease features confirmed that a synergistic effect of imatinib and bosutinib can be achieved. We analyzed the combination effect in cells derived from three Ph observed. This patient started imatinib therapy (800 mg per day) achieving a complete hematological response, complete cytogenetic and molecular responses. All three patients were studied without cytogenetic response (20/20 Ph þ metaphases); no additional chromosomal abnormalities were evident. Patients 1 and 2 were studied at the time of imatinib resistance, and patient 3 was studied at diagnosis. Fresh peripheral blood mononuclear leukemic cells from these patients were analyzed in a proliferation assay after 5 days of treatment with the inhibitors either alone or in combination across a wide range of concentration and at three ratios ( Figure 3) . Synergism was evaluated and CI values are reported in Table 2 . Although positive cooperation was observed in all the samples analyzed, the synergistic effect varied, depending on the sensitivity level to imatinib treatment. Cells from patient 2 benefited to a lesser extent from the combined treatment due to the presence of a known resistant mutation, whereas in cells from patient 3, which were sensitive to imatinib, a strong synergistic effect could be observed.
In this study, we investigated the effect of combining imatinib and bosutinib in leukemic cell lines that are sensitive or resistant to imatinib as well as in fresh leukemic cells derived from CML patients with different disease features.
Further characterization of the combined treatment is required, especially for the toxicity profile. However, the results obtained in vitro in Bcr-Abl-negative cells Ba/F3 and U937 show that no increase in general toxicity was detected. The positive cooperation observed in our experiments could be explained by the different binding modes of bosutinib and imatinib. Bosutinib is able to bind Bcr-Abl in the intermediate conformation, 2 whereas imatinib binds only the inactive conformation of the enzyme. Using the drugs simultaneously would facilitate targeting a greater proportion of the Bcr-Abl population, accounting for the positive effect observed in our assays and the generally greater synergy achieved with this combination compared to those obtained combining imatinib with nilotinib 8 that share a common binding mode. Furthermore, we hypothesized that the simultaneous presence of the two drugs could lead to the inhibition of drug efflux transporters. A similar mechanism was also suggested to explain synergism between imatinib and nilotinib, 9 showing that imatinib is able to increase the intracellular concentration of nilotinib through inhibition of P-gp, of which nilotinib is a substrate. To investigate this hypothesis, we performed an intracellular uptake and retention assay using radiolabeled bosutinib. The presence of different concentration of imatinib, however, did not lead to increased bosutinib intracellular concentration (data not shown).
The potential advantages offered by a combined treatment are represented by the possibility to obtain a higher Bcr-Abl inhibition and to target a wide panel of mutant forms of Bcr-Abl thus reducing the risk of acquired drug resistance development. Moreover, because of the higher activity of the combination against wild-type form of Bcr-Abl, this therapeutic approach could produce an improved molecular response in newly diagnosed patients with CML. The use of the combined treatment as an upfront therapy could reduce the risk to generate resistant clones and could increase the probability to eradicate the disease.
Conflict of interest
Dr Frank Boschelli is employee at Pfizer Research, which is developing bosutinib for treatment of CML. No other conflict of interest to disclose. Combination index (CI) calculated from the dose-response curves presented in Figure 5 . Values are representative of at least two independent experiments. For each patient, the most significant ratio between bosutinib and imatinib is presented. CI values o1, ¼ 1 or 41 indicate synergistic, additive or antagonistic interactions, respectively. Synergism levels are indicated according to Chou and co-workers, 5 based on the average CI.
Letters to the Editor
The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development The serum response transcription factor (Srf) controls developmental programs and proliferation, differentiation, cellular shape and cytoskeleton organization. Its activity is regulated through the mitogen-activated protein kinase pathway (MAPK)/ Erk pathway and the GTPases Rho/mDia/actin pathway, allowing integration of extracellular mitogenic signals with changes in actin cytoskeleton. The Srf co-activators myocardinrelated transcription factors (Mrtfs) assist Srf in the expression of genes linked to actin cytoskeleton dynamics. Among Mrtfs, the megakaryocytic acute leukemia (MAL) (also known as Mrtf-A and megakaryoblastic leukemia-1) is an actin-binding protein whose nuclear accumulation is controlled by the actin treadmilling cycle. 1, 2 The human MAL gene is fused to the OTT/ RBM15 gene in acute megakaryoblastic leukemia (AMKL) 3, 4 and a contribution of Mal activity to the late steps of murine and human megakaryopoiesis has been reported. 5, 6 Although the lack of Srf results in major cellular defects and embryonic lethality (reviewed in Miano et al. 7 ), Mal germ line deficiency results in a limited myoepithelial cells phenotype 8, 9 probably because of the redundancies of Mrtf proteins.
To gain insight into the role of Srf and Mal in megakaryocyte (Mk) development, we compared the defects induced by their lossof-function in adult hematopoietic cells. Srf flx mice 10 were bred with polyinosine-polycytidine-inducible Mx1-Cre mice, 11 then analyzed 5 weeks post-induction (Supplementary Figure 1) . The Mal/Mrft-A À/À mice have been reported. 9 Null animals showed thrombocytopenia with 72 and 25% of wild-type average platelet counts for Mal À/À and Srf D/D; MxÀCre respectively ( Figure 1a) . In vivo, Mal-and Srf-null platelet half-life was similar to control, indicating that the thrombocytopenia was not the result of an accelerated clearance (Supplementary Figure 2) . In spite of the thrombocytopenia, immunochemical (Figure 1b) and flow cytometric (Figure 1c ) analyses showed accumulation of bone marrow (BM) Mks in null animals. Srf and Mal were dispensable for the control of ploidy (Supplementary Figure 3) . However, both mutant cells showed a diminished capacity to form proplatelet (PP) structures in culture medium, with less than half of them showing short cytoplasmic extensions resembling PPs, when compared with normal counterparts (Figure 1d ). Transmission electron microscopy revealed major alterations in Srf-null Mks morphology with cytoplasmic fragments scattered throughout the BM space and naked nuclei, suggesting that Mks had fragmented in situ (Figure 2iv) . No platelets were observed, further underscoring an abnormal fragmentation within the marrow. Circulating platelets had an altered morphology with an increase in mean platelet volume of around 30% (Figure 1a ) and the macrothrombocytopenia was confirmed by ultra-structure (Figure 2viii ). Morphology of Mal-null Mks was less altered. A majority of them were extremely mature, with well-developed demarcation membranes and randomly scattered -granules, and showed some cytoplasmic extensions with a thin outer ring of cytoplasm suggesting that they were beginning to form PPs in the marrow; very few showed a smooth surface (Figure 2ii ). In agreement, numerous deposits of von Willebrand factor (vWF) immunostaining were scattered in BM space, indicating that local platelet production had occurred (Figure 1b) . Mal À/À platelets were associated with an elongated shape and less -granules than their wild-type counterparts (Figure 2vi ). Flow cytometry analyses showed normal numbers and frequencies of megakaryocyte-erythroid progenitors (MEP; Supplementary Figure 4 ) in null-BMs while committed megakaryocytic progenitors accumulated in the BM (Figure 1e ). This was confirmed by colony formation assays showing an increased numbers of colony-forming unit (CFU)-Mk (Figure 1f) . In vitro cultures also revealed excess of isolated Mks (Figure 1f ) indicating an increased in late CFU-Mk. These data suggest that Srf and Mal contribute to the megakaryopoiesis at a similar stage.
We analyzed by quantitative reverse transcriptase-PCR (RT-PCR), the expression levels of several Srf target genes and genes linked to the formation of cytoskeletal structures (Figure 3 ). Tropomyosin 1 (Tpm1), Actin B (Actb) and Filamin A (Flna) genes, which participate in the organization of Mk and platelet actin cytoskeleton, were markedly under expressed in the two null genotypes, indicating a contribution of the Srf/Mal complex to their expression. A low expression of the matrix metallopeptidase 9 (Mmp9) and myosin light chain 9 (Myl9)/Mlc2 genes, known as MAL/SRF targets 5, 12 was observed. The abnormal
